Macquarie Group
ABOS icon

Macquarie Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Macquarie Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,247
Closed -$5 – 1889
2024
Q1 		$5 Buy
+1,247
New +$4.7K ﹤0.01% 1778

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Macquarie Group's ABOS Position: Q2 2024 in Review

Macquarie Group sold out of Acumen Pharmaceuticals (ABOS) in Q2 2024, closing a stake of 1,247 shares — an estimated $5 sold.

Macquarie Group first reported a position in ABOS in Q1 2024 and held it in 1 quarter. The position peaked at $5 in Q1 2024. 81 funds tracked by Wall St. Rank hold ABOS as of Q2 2024.

  • Macquarie Group reported no remaining Acumen Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 1,247 Acumen Pharmaceuticals shares in Q2 2024, an estimated $5.
  • Macquarie Group first reported a position in Acumen Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Macquarie Group's Acumen Pharmaceuticals position peaked at $5 in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.